FI3229776T3 - Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt - Google Patents

Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt Download PDF

Info

Publication number
FI3229776T3
FI3229776T3 FIEP15800777.3T FI15800777T FI3229776T3 FI 3229776 T3 FI3229776 T3 FI 3229776T3 FI 15800777 T FI15800777 T FI 15800777T FI 3229776 T3 FI3229776 T3 FI 3229776T3
Authority
FI
Finland
Prior art keywords
compound
pharmaceutical
pharmaceutical compound
pharmaceutical composition
biocompatible
Prior art date
Application number
FIEP15800777.3T
Other languages
English (en)
Finnish (fi)
Inventor
Matthieu Germain
Marie-Edith Meyre
Agnès Pottier
Laurent Levy
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Application granted granted Critical
Publication of FI3229776T3 publication Critical patent/FI3229776T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP15800777.3T 2014-11-25 2015-11-24 Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt FI3229776T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306874 2014-11-25
PCT/EP2015/077446 WO2016083343A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof

Publications (1)

Publication Number Publication Date
FI3229776T3 true FI3229776T3 (fi) 2023-08-15

Family

ID=52013981

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15800777.3T FI3229776T3 (fi) 2014-11-25 2015-11-24 Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt

Country Status (13)

Country Link
US (2) US10391058B2 (enExample)
EP (1) EP3229776B1 (enExample)
JP (1) JP6836510B2 (enExample)
AR (1) AR102781A1 (enExample)
DK (1) DK3229776T3 (enExample)
ES (1) ES2951598T3 (enExample)
FI (1) FI3229776T3 (enExample)
HU (1) HUE062561T2 (enExample)
LT (1) LT3229776T (enExample)
PL (1) PL3229776T3 (enExample)
PT (1) PT3229776T (enExample)
TW (1) TW201628654A (enExample)
WO (1) WO2016083343A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
TW201628644A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
CN115137822B (zh) * 2022-06-13 2023-06-23 武汉大学中南医院 一种光热热电一体化的抗肿瘤植入体的制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
US6160006A (en) 1996-10-18 2000-12-12 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
BR9812131A (pt) 1997-08-19 2000-07-18 Warner Lambert Co Composições contendo bergamotina para aumentar a biodisponibilidade oral de agentes farmacêuticos
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MXPA02012817A (es) * 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP5513708B2 (ja) 2003-12-22 2014-06-04 ブラッコ・シュイス・ソシエテ・アノニム 造影イメージング用の気体封入マイクロベシクル・アセンブリー
JP2007523090A (ja) * 2004-02-10 2007-08-16 バーンズ−ジューイッシュ ホスピタル デコイ系を用いたターゲティングされた微粒子剤の有効性および安全性の改善方法
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
WO2007128066A1 (en) 2006-05-04 2007-11-15 University Of South Australia Drug release from nanoparticle-coated capsules
KR20100095507A (ko) 2007-08-21 2010-08-31 알자 코퍼레이션 보론산 화합물의 생체내 투여를 위한 리포좀 조성물
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EP2537530A4 (en) 2010-02-17 2015-12-16 Nat Univ Corp Univ Kobe RADIATION MEANS
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
JP6158714B2 (ja) 2011-01-31 2017-07-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ ナノ粒子デリバリーシステム、その製造および使用
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
TW201628644A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
CN107106505A (zh) 2014-11-25 2017-08-29 纳米生物技术公司 药物组合物、其制备和用途

Also Published As

Publication number Publication date
HUE062561T2 (hu) 2023-11-28
EP3229776A1 (en) 2017-10-18
JP2018504450A (ja) 2018-02-15
DK3229776T3 (da) 2023-07-31
WO2016083343A1 (en) 2016-06-02
US20170258717A1 (en) 2017-09-14
ES2951598T3 (es) 2023-10-23
PL3229776T3 (pl) 2023-11-06
LT3229776T (lt) 2023-08-25
US10391058B2 (en) 2019-08-27
AR102781A1 (es) 2017-03-22
EP3229776B1 (en) 2023-06-28
JP6836510B2 (ja) 2021-03-03
PT3229776T (pt) 2023-08-17
TW201628654A (zh) 2016-08-16
US11471410B2 (en) 2022-10-18
US20190374465A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
FI3229776T3 (fi) Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
PE20091184A1 (es) Formas de dosificacion farmaceutica
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
JP2013503174A5 (enExample)
RU2012157805A (ru) Способы лечения рака мочевого пузыря
HK1222563A1 (zh) 药物组合物、制备及其用途
MX388073B (es) Composición farmacéutica, preparación y usos de la misma.
HK1208162A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
EP2853543A8 (en) Anti-blys antibody
MX2022003458A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
BR112014003061A2 (pt) composição farmacêutica com sabor mascarado
EP2527429A3 (en) DAC HYP compositions and methods
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
WO2014106116A8 (en) Therapeutic compositions comprising antibodies
AR102779A1 (es) Composición farmacéutica, su preparación y sus usos
WO2018050942A8 (es) Nanopartículas con interiores protegidos, y métodos de uso de las mismas
EA201892797A1 (ru) Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
JP2018513142A5 (enExample)
WO2014194250A3 (en) Novel nanocarrier delivered cancer chemotherapeutic agents
WO2017118114A1 (zh) 一种由常山酮和青蒿倍半萜内酯类化合物组成的抗癌组合物及其应用
BR112013010714A2 (pt) Composição farmacêutica e uso de um composto antibiótico
WO2009088831A3 (en) Method of inhibiting abcg2 and other treatment methods